Haisco(SZ:002653) Xin Lang Cai Jing·2025-09-09 02:16Core Viewpoint - The stock of Haishike has shown significant growth this year, with an 80.53% increase, despite a recent decline in net profit [1][2]. Financial Performance - As of June 30, 2025, Haishike reported a revenue of 2.001 billion yuan, representing a year-on-year growth of 18.63% [2]. - The net profit attributable to shareholders was 129 million yuan, which is a decrease of 21.79% compared to the previous period [2]. - Cumulative cash dividends since the A-share listing amount to 3.673 billion yuan, with 687 million yuan distributed over the last three years [3]. Stock Market Activity - On September 9, Haishike's stock price rose by 2.04%, reaching 59.54 yuan per share, with a total market capitalization of 66.68 billion yuan [1]. - The stock has seen a trading volume of 80.54 million yuan, with a turnover rate of 0.28% [1]. - The stock's performance over various time frames includes a 3.82% increase over the last five trading days, a 4.55% increase over the last 20 days, and a 39.47% increase over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400 [2]. - The average number of circulating shares per shareholder decreased by 28.64% to 42,147 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A, with both increasing their holdings [3].